Literature DB >> 9621067

Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

N L Michael1, J A Nelson, V N KewalRamani, G Chang, S J O'Brien, J R Mascola, B Volsky, M Louder, G C White, D R Littman, R Swanstrom, T R O'Brien.   

Abstract

Individuals who are homozygous for the 32-bp deletion in the gene coding for the chemokine receptor and major human immunodeficiency virus type 1 (HIV-1) coreceptor CCR5 (CCR5 -/-) lack functional cell surface CCR5 molecules and are relatively resistant to HIV-1 infection. HIV-1 infection in CCR5 -/- individuals, although rare, has been increasingly documented. We now report that the viral quasispecies from one such individual throughout disease is homogenous, T cell line tropic, and phenotypically syncytium inducing (SI); exclusively uses CXCR4; and replicates well in CCR5 -/- primary T cells. The recently discovered coreceptors BOB and Bonzo are not used. Although early and persistent SI variants have been described in longitudinal studies, this is the first demonstration of exclusive and persistent CXCR4 usage. With the caveat that the earliest viruses available from this subject were from approximately 4 years following primary infection, these data suggest that HIV-1 infection can be mediated and persistently maintained by viruses which exclusively utilize CXCR4. The lack of evolution toward the available minor coreceptors in this subject underscores the dominant biological roles of the major coreceptors CCR5 and CXCR4. This and two similar subjects (R. Biti, R. Ffrench, J. Young, B. Bennetts, G. Stewart, and T. Liang, Nat. Med. 3:252-253, 1997; I. Theodoreu, L. Meyer, M. Magierowska, C. Katlama, and C. Rouzioux, Lancet 349:1219-1220, 1997) showed relatively rapid CD4+ T-cell declines despite average or low initial viral RNA load. Since viruses which use CXCR4 exclusively cannot infect macrophages, these data have implications for the relative infection of the T-cell compartment versus the macrophage compartment in vivo and for the development of CCR5-based therapeutics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621067      PMCID: PMC110409     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.

Authors:  A J Japour; S A Fiscus; J M Arduino; D L Mayers; P S Reichelderfer; D R Kuritzkes
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

6.  The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.

Authors:  N L Michael; G Chang; L G Louie; J R Mascola; D Dondero; D L Birx; H W Sheppard
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

7.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

8.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

9.  Molecular cloning and functional expression of a new human CC-chemokine receptor gene.

Authors:  M Samson; O Labbe; C Mollereau; G Vassart; M Parmentier
Journal:  Biochemistry       Date:  1996-03-19       Impact factor: 3.162

10.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.

Authors:  P Lusso; F Cocchi; C Balotta; P D Markham; A Louie; P Farci; R Pal; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  54 in total

1.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV.

Authors:  A D Sullivan; J Wigginton; D Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

3.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Authors:  B Schramm; M L Penn; R F Speck; S Y Chan; E De Clercq; D Schols; R I Connor; M A Goldsmith
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

6.  Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.

Authors:  Carina A Rodriguez; Sarah Koch; Maureen Goodenow; John W Sleasman
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  Counterpoint: Cord blood stem cell therapy for acquired immune deficiency syndrome.

Authors:  Ghalib Alkhatib
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

8.  HIV-1 Nef responsiveness is determined by Env variable regions involved in trimer association and correlates with neutralization sensitivity.

Authors:  Yoshiko Usami; Heinrich Göttlinger
Journal:  Cell Rep       Date:  2013-10-24       Impact factor: 9.423

9.  Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.

Authors:  Y J Zhang; T Dragic; Y Cao; L Kostrikis; D S Kwon; D R Littman; V N KewalRamani; J P Moore
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.

Authors:  Lachlan Gray; Melissa J Churchill; Niamh Keane; Jasminka Sterjovski; Anne M Ellett; Damian F J Purcell; Pantelis Poumbourios; Chenda Kol; Bin Wang; Nitin K Saksena; Steven L Wesselingh; Patricia Price; Martyn French; Dana Gabuzda; Paul R Gorry
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.